PRAX Nov 2024 80.000 call
| Previous Close | 5.25 |
| Open | 5.25 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 80.00 |
| Expire Date | 2024-11-15 |
| Day's Range | 5.25 - 5.25 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
GlobeNewswirePraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, June 04, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on June 3, 2024, the Compensation Committee of Praxis’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 300 shares of its common stock and r
Simply Wall St.This Is Why Praxis Precision Medicines, Inc.'s (NASDAQ:PRAX) CEO Compensation Looks Appropriate
Key Insights Praxis Precision Medicines will host its Annual General Meeting on 5th of June Salary of US$625.0k is part...
- GlobeNewswire
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
BOSTON, May 17, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will be participating in three upcoming conferences. Praxis management will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conferenc
